SynCo Bio Partners

IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024

Retrieved on: 
Wednesday, December 13, 2023
Biotechnology, Pharmaceutical, Health, SynCo Bio Partners, NYSE, Conference, IGC

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American: IGC) today announced that the Company’s management team will participate in Biotech Showcase and BIO Partnering @ JPM, held in-person and scheduled alongside the J.P. Morgan 41st Annual Healthcare Conference 2024.

Key Points: 
  • IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American: IGC) today announced that the Company’s management team will participate in Biotech Showcase and BIO Partnering @ JPM, held in-person and scheduled alongside the J.P. Morgan 41st Annual Healthcare Conference 2024.
  • Details of the events are as follows:
    Location: Hilton San Francisco – Union Square, Yosemite A (Ballroom Level)
    During all listed conferences, members of the IGC management team will conduct one-on-one meetings with registered investors and pharmaceutical companies, showcasing the Company’s business strategy, recent partnerships and achievements, and anticipated milestones.
  • In addition, IGC Pharma will concurrently host one-on-one meetings in San Francisco during JPM Week.
  • If you would like to schedule a meeting, please [email protected] .

Organic Wholesaler Bio Partner Outpacing the Competition with Infor's Industry Cloud Service

Retrieved on: 
Wednesday, December 6, 2023
Amazon Web Services, Food, ERP, SynCo Bio Partners, Vegetable, AWS, ICT, Infor, Video game, Drink

MUNICH, Dec. 6, 2023 /PRNewswire/ -- Infor®, the industry cloud company, today announced that Swiss food wholesaler Bio Partner has successfully implemented Infor CloudSuite Food & Beverage. Besides automating and accelerating business processes, the company benefits from the scalability, security and innovation of the Infor cloud platform powered by Amazon Web Services (AWS).

Key Points: 
  • MUNICH, Dec. 6, 2023 /PRNewswire/ -- Infor®, the industry cloud company, today announced that Swiss food wholesaler Bio Partner has successfully implemented Infor CloudSuite Food & Beverage.
  • Bio Partner Schweiz AG is the leading wholesale partner in the Swiss organic food market, based in Seon (Canton Aargau).
  • Due to the ongoing trend toward sustainable and organic food, demand at Bio Partner is growing, and the resulting business challenges are growing, too.
  • Infor's industry cloud solution impressed with its baked-in food and beverage wholesale capabilities and future-proof innovations, helping Bio Partner to outpace the competition.

Aileron Therapeutics Announces Acquisition of Lung Therapeutics

Retrieved on: 
Tuesday, October 31, 2023
Survival, Sale, SynCo Bio Partners, AEC, Xbox Series X and Series S, Molecular biology, EDT, Fibrosis, Idiopathic pulmonary fibrosis, Acquisition, AEC Routemaster, United, IPF, Lung, Bios, Interim, University, ALRN, Therapy, Patient, Diagnosis, Moses Austin, Pharmaceutical industry, Management, Aileron

WALTHAM, Mass. and AUSTIN, Texas, Oct. 31, 2023 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN) today announced it has acquired Lung Therapeutics, Inc. ("Lung Tx"), a privately held biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications that have no approved or limited effective treatments. Immediately following the acquisition of Lung Tx, Aileron entered into a definitive agreement for the sale of shares of Aileron's Series X non-voting convertible preferred stock (the "Series X preferred stock") and warrants to purchase shares of Aileron's common stock in a private placement to a group of accredited investors led by Bios Partners ("Bios"), and including Nantahala Capital, as well as additional undisclosed investors. The private placement is expected to result in gross proceeds to Aileron of approximately $18 million before deducting placement agent fees and other offering expenses. Aileron intends to use the proceeds from the private placement primarily to complete the ongoing Phase 1b clinical study of LTI-03, a Caveolin-1-related peptide in development for the treatment of IPF, and for general corporate purposes. 

Key Points: 
  • and AUSTIN, Texas, Oct. 31, 2023 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN) today announced it has acquired Lung Therapeutics, Inc. ("Lung Tx"), a privately held biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications that have no approved or limited effective treatments.
  • "We are pleased to announce that after a thorough evaluation of strategic alternatives, we have completed the acquisition of Lung Therapeutics, which we believe represents a value-creation opportunity for Aileron's stockholders.
  • "Lung Therapeutics has built a promising clinical-stage pipeline for life-threatening lung conditions, and we believe in the ability of our combined companies to deliver value to both patients and stockholders."
  • I want to thank the board and entire team of Lung Therapeutics for all their hard work with this transaction."

Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer

Retrieved on: 
Tuesday, July 11, 2023
University College London, Yale University, Emergency medicine, Drug development, Pediatrics, Master of Philosophy, Associate, Synthetic biology, Patient, Faculty, Knowledge, Netherton syndrome, NYSE, SynCo Bio Partners, Skin, Pharmaceutical industry, Netherton

BRANFORD, Conn., July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the appointment of Travis Whitfill as Chief Operating Officer.

Key Points: 
  • BRANFORD, Conn., July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the appointment of Travis Whitfill as Chief Operating Officer.
  • Mr. Whitfill is the cofounder of Azitra and joins from Bios Partners, a venture capital firm focused on investing in early-stage biopharmaceutical companies.
  • "Travis brings a wealth of knowledge in biotech, synthetic biology, and drug development.
  • The company is at an exciting juncture as it begins clinical trials in Netherton syndrome," said Mr. Whitfill.

ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial

Retrieved on: 
Wednesday, March 8, 2023
IND, Retina, RRD, Neuroprotection, Therapy, OAG, ONL, University, City Commercial Center, SynCo Bio Partners, Geographic atrophy, Ophthalmology, Patient, Venture round, ANN, Pharmaceutical industry

ANN ARBOR, Mich., March 08, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced it has closed on the first tranche of a $15 million Series C Preferred Stock financing round.

Key Points: 
  • ANN ARBOR, Mich., March 08, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced it has closed on the first tranche of a $15 million Series C Preferred Stock financing round.
  • Proceeds from the financing will primarily support the advancement of ONL1204 Ophthalmic Solution into a Phase 2 clinical trial in patients with macula-off rhegmatogenous retinal detachment (RRD).
  • “With the support of our current and new investors, coupled with the opening of our IND for ONL1204 last month, we are grateful for the opportunity to advance our lead asset into a later stage Phase 2 clinical study,” said David Esposito, chief executive officer of ONL Therapeutics.
  • In addition to the Phase 2 study in RRD, the first tranche of Series C financing will also support the Company’s regulatory preparations for Phase 2 programs in GA and OAG.

Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023"

Retrieved on: 
Wednesday, December 21, 2022
JPM, SynCo Bio Partners, Therapy, Conference, Cognition, Ellis Street Graded School Historic District

PURCHASE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that the Company’s management team will participate in the 6th Annual Sachs Neuroscience Forum, Biotech Showcase and BIO Partnering @ JPM.

Key Points: 
  • PURCHASE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that the Company’s management team will participate in the 6th Annual Sachs Neuroscience Forum, Biotech Showcase and BIO Partnering @ JPM.
  • All events will be held in-person and are scheduled alongside the J.P. Morgan 41st Annual Healthcare Conference 2023.
  • In addition, Cognition will concurrently host one-on-one meetings at the Hotel Fusion located at 140 Ellis Street in San Francisco during JPM Week.
  • If you would like to schedule a meeting, please email Daniel Kontoh-Boateng, [email protected] or Rosalyn Christian, [email protected] .

Optimize your time and investment by downloading a networking info app for the 41st Annual JP Morgan Health Care Conference

Retrieved on: 
Monday, December 12, 2022
Conference, BIO, JPM, Biotechnology Innovation Organization, Biotechnology, Android, Organization, Good Day, SynCo Bio Partners, Politics, Research, Policy, Therapy, Pharmaceutical industry, Online shopping, Apple

Organizations can also use the app to list their scheduled events being held during the conference timeframe.

Key Points: 
  • Organizations can also use the app to list their scheduled events being held during the conference timeframe.
  • Novateur is delighted to be collaborating with BIO, to give the app a global reach," says Ali Ardakani, Founder and Managing Director of Novateur Ventures.
  • “I see the app as a natural addition to BIO Partnering at JPM Week.
  • If you are an industry event sponsor and would like your event to be featured in the app, click here .

Transgene Announces Upcoming Investor Meetings

Retrieved on: 
Thursday, December 15, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Conference, Immunotherapy, Management, Vaccination, Artificial intelligence, NEC, BIO, Cancer, JPM, TNG, SynCo Bio Partners, Potyvirus, Precision medicine, AstraZeneca, Nightclub, Vaccine, Euronext

TRANSGENE (Paris:TNG) today announces that Management will participate in several investor events in January and February 2023, as set out below.

Key Points: 
  • TRANSGENE (Paris:TNG) today announces that Management will participate in several investor events in January and February 2023, as set out below.
  • The Company will also attend:
    26th ODDO BHF Forum (virtual): January 9-10, 2023;
    Degroof Petercams Virtual Healthcare Conference: January 27, 2023;
    BIO CEO & Investor Forum (New York): February 6-9, 2023.
  • Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer.
  • With its proprietary platform Invir.IO, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.